Introduction: This study was performed to assess the relationship between tumour response and radiation dose in equivalent 2 Gy per fraction (EQD2). Method: A retrospective cohort analysis of 21 patients with a diagnosis of intracranial haemangiopericytoma between 2000 and 2013 was included in this study. A total of 39 lesions were analysed. The equivalent dose in 2 Gy per fraction was calculated by assigning an alpha-beta ratio of 12 Gy. A paired t-test compared dose (EQD2) and tumour response, and as the outcome was binary, a logistic regression analysis was performed. Results: In total, there were 14 cases of progression and 25 cases of nonprogression. It was estimated that for a one unit increase in EQD2, the odds of non-progression were increased by a factor of 1.13 (P = 0.026). After adjusting for PTV volume, the estimated effect of EQD2 (min) on tumour response was stronger, with an estimated odds ratio of 1.36 for an increase of one unit and an odds ratio of 21.6 for an increase of 10 units (P = 0.015). The dose range varied with varying PTV volumes. Based on the logistic model, the probability of having non-progression is larger than 50% for EQ2Dmin doses larger than 30-40 Gy, in particular for volumes larger than 3.67 cm 3 .
Introduction
Haemangiopericytoma (HPC) is a rare and highly vascular neoplasm thought to be derived from Zimmerman pericytes, cells found anywhere that capillaries occur throughout the body. The natural history, optimal treatment and clinical outcome are not well understood. They are biologically aggressive tumours. Local recurrences, intracranial metastases and extracranial metastases are common. 1 The primary mode of treatment for haemangiopericytoma is surgery. It is proven that it is difficult to cure the disease with surgical resection alone. 1 Experience from the SEER database recommends that post-operative limited field radiotherapy is considered in patients with a subtotal resection as it is associated with a significantly better survival. 2 However, there are few treatment options for HPCs that recur, even after surgical resection followed by adjuvant RT, particularly when the recurrent tumours are located in eloquent or deep-seated areas. Although adjuvant chemotherapy, repeated conformal RT and radiosurgery have been tried, the efficacy of these salvage treatments for recurrent intracranial HPCs remains unclear due to the scarcity and insufficiency of clinical data. 3 Radiotherapy was introduced as a treatment option for the management of intracranial haemangiopericytoma recurring after surgical resection. There have been studies that have demonstrated that radiotherapy using the stereotactic approach provides safe delivery of a relative high dose to a well-defined volume. In addition, this modality allows for re-treatment for recurrences. 1 In saying that, only a few studies using stereotactic radiotherapy have been reported to date. [4] [5] [6] [7] [8] The optimum dose, however, for successful local control of haemangiopericytoma without adverse events remains unclear.
The aim of this study is to assess the relationship of radiation dose in equivalent 2 Gy per fraction and tumour response in patients with intracranial haemangiopericytoma as this will be a step closer to determine the optimum dose of radiation to treat patients with this rare condition.
Methods

Clinical data
A cohort of 21 patients treated between 2000 and 2013 was retrieved from the treatment planning system (TPS) at Alfred Health Radiation Oncology. Diagnoses of all patients were confirmed histopathologically after surgical resection, prior to stereotactic radiotherapy. A total of 39 lesions were analysed, 13 were locally recurrent tumours at the operative bed and the other 26 lesions were metastatic intracranial tumours distant from the original tumour location. The median age of the patients treated was 51 (19-76) and 71% of the patients in this study were female.
These patients were all treated with intracranial stereotactic radiosurgery in a single institution and the treatment delivery varied depending on the time of treatment. Patients who were treated before 2003 were planned with the BrainScan TPS (Brainlab, Munich, Germany), and the actual delivery was performed with an xKnife radiosurgery system (Radionics). MRI was used in radiotherapy planning, and the sequences utilized were axial and coronal T1 sequence with contrast (Gad) and T2 sequence. Immobilization was achieved by using an intracranial stereotactic frame fixed to the skull for 1 fraction radiosurgery with a mouth bite. Patients who received therapy after 2003 were treated with a Brainlab m3 MLC add-on installed on a Varian Linear Accelerator, which was replaced in 2006 by a Novalis Classic machine equipped with a robotic couch with 6 degrees of freedom. Planning was performed with the iPlan TPS. The planning target volume (PTV) and organs at risk (OAR) were outlined consistently by the same treating oncologist. Following treatment, all patients underwent clinical evaluation with accompanying imaging in the form of an MRI approximately twice a year for the first 2 years and yearly thereafter.
Analysis
For each dosimetric parameter, the equivalent dose in 2 Gy per fraction (EQD2) was calculated by assigning an a-b ratio of 12 Gy. This value was chosen from experience acquired with the Lexsell Gamma knife as previously reported by Yuan et al. 8 The data were predominantly brain metastases, but it is the closest representation to simulate a high-grade brain tumour ( Fig. 1) . Each tumour was categorized into one of two outcomes following completion of treatment. Tumour response was defined as progression and non-progression. This was assessed with serial MRI imaging at 6 months following treatment. Progression of disease was further defined as radiological increase in size of the tumour on MRI imaging. Progression was defined as 20% increase (>/= 5 mm absolute increase) in the sum of the longest diameter recorded since treatment started. Non-progression was defined as stable (no increase or decrease in the size of the lesion), or a radiological reduction in size of the lesion on MRI imaging.
Then, univariate logistic regression was used to assess the relationship between tumour non-progression and the EQD2 for Dmin (minimum dose given to the PTV, here defined as EQD2 min) as this was deemed to be an appropriate parameter in assessing dose-response. A median dose of 22.5 Gy (12-68 Gy) was prescribed, and the median number of fractions prescribed was 15 (1-30). For single fraction treatment, the median dose prescribed was 22.5 Gy (12-25 Gy). For a three fraction treatment, the median dose prescribed was 22.5 Gy (22.5-26.25 Gy). The median dose prescribed for a 15 fraction treatment was 44.4 Gy (35-46.25 Gy). For a 25 fraction treatment, the median dose prescribed was 58 Gy (47.3-68.7 Gy).
Finally, multivariate logistic regression was also performed to assess the influence of other clinical factors such as the PTV volume. All analyses were done by using the R project software. A follow-up period of at least 6 months was considered an appropriate period to perform the analysis.
Results
A total of 39 plans were analysed, for each of them, the volume of the PTV, the minimum dose (Dmin), the mean dose (Dmean) and the maximum dose (Dmax) were recorded. The PTV covered a wide range between 0.08 Zealand College of Radiologists and 221 cm 3 . We elected to use the PTV in the analysis as we felt that this volume most reflected the irradiated volume, which included the gross disease accounting for microscopic spread and set up error. In total, there were 14 cases of progression and 25 cases of non-progression. The main variable of interest was the continuous variable, EQD2 (min). The univariate logistic regression showed that the PTV EQD2 min was significantly correlated with the probability of non-progression of the tumour (Table 1) .
It was estimated that for a single-unit increase in EQD2 min, the odds of non-progression increased by a factor of 1.13. For 95% confidence, the true odds ratio was between 1.01 and 1.26 (Table 2 ).
An accuracy of the test depends on how well the test separates the 2 groups and it is measured by the area under the curve. An area of 1 represents a perfect test and 0.5 represents a test that is suboptimal. The area under the curve of this model was 0.7 which is fair. However, by looking at the relationship between the observed outcome and the modelled outcome, the calibration of the model was suboptimal for low outcome probabilities probably due to the small number of patients in this dose range group (goodness of fit = 0.2). This effect was then scaled up to a larger increase in EQD2 min of the order of 10 units as it could be a clinically significant change in radiation. This process does not change the model but simply expresses the estimated change in odds over a different scale for EQD2 min. It was estimated that for a 10 unit increase in EQD2 min, the odds of non-progression were increased by a factor of 2.29. For 95% confidence, the true odds ratio was between 1.10 and 10.09.
This dose-response model shows that for lower values of EQD2 min, the probability of non-progression is lower than for larger doses, confirming the relationship between dose delivered to the PTV and probability of non-progression. The wide confidence intervals suggest that these estimates are only accurate to AE20% at the midrange of EQD2 min and as much as AE40 or 60% at the extremes. This is due to the small numbers of observations at the extremes and the overlap in non-progression and progression cases in the middle dose range. The graph also confirms the poor calibration of the model at lower doses, once again most likely due to the small number of observations.
In order to improve the calibration of the model, we included PTV to the multivariate logistic regression. It was noted that the size of the PTV was statistically significant correlating to the probability of non-progression (Table 3) . It also significantly improved the AUC (AUC = 0.915).
As shown, this model clearly improves calibration and identifies the probability of non-progression given a certain EQD2 min to the PTV as the curve is steeper than the model shown in Figure 2 . Based on the logistic model, the probability of having non-progression is larger than 50% for EQ2Dmin doses larger than 30-40 Gy in particular for volumes larger than 3.67 cm 3 (Table 4) .
Discussion
Haemangiopericytoma is an uncommon neoplasm arising from Zimmerman pericytes around capillaries and postcapillary venules. These tumours comprise <2.5% of meningeal tumours and <1% of all intracranial tumours. They are aggressive tumours that tend to recur even after macroscopic total resection. They can recur locally or distantly in the neural axis, as well as distant extraneural metastases. 9, 10 According to findings from several studies, radiotherapy is an effective treatment for intracranial haemangiopericytoma. In a report by Sheehan et al., 6 the authors reviewed a series of 15 patients with 15 recurrent haemangiopericytoma who were treated with stereotactic radiosurgery. On follow up imaging, 12 of the 15 tumours had regressed and three had become Our retrospective study looked at 39 lesions in 21 patients treated at Alfred Health Radiation Oncology. Out of the 39 haemangiopericytoma lesions, 25 of them demonstrated non-progression and 14 lesions progressed. A logistic regression analysis was performed on our data to assess relationship of dose in 2 Gy per fraction and tumour response adjusted for PTV volume. This model predicted that for one unit increase in dose (EQD2), the odds of non-progression are increased by factor of 1.13. (P = 0.026). With a 10 unit increase in dose (EQD2), the odds of non-progression are increased by a factor of 2.29 (P = 0.026). We also found that with lower doses prescribed the estimated probability of nonprogression is lower and with higher doses the estimated probability of non-progression is more pronounced. When the model is adjusted for PTV volume, this better distinguishes dose-response in regard to progression and non-progression as the curve becomes steeper (Fig. 3) . We noted that the probability of having non-progression is larger than 50% for EQ2Dmin doses larger than 30-40 Gy in particular for volumes larger than 3.67 cm 3 .
The linear-quadratic model has been challenged in the setting of extreme hypofractionation. However, there has been recent analyses of the clinical outcomes covering 'conventional' hyper-to extreme hypofractionation (stereotactic ablative radiotherapy) regimes which appear to be consistent with the linear-quadratic radiobiology, even at the largest fraction sizes, despite there being theoretical reasons to expect 'LQ violation' above a certain dose.
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Based on this statistical observation, the optimal doses of treating these tumours vary depending on the size of the PTV. There would be other confounding variables that one should take into account when determining the optimal dose. These include the age of the patient, location of the tumour, extent of surgical resection, WHO grade of the tumour, performance status at the time of treatment and comorbidities. The study suggests an optimum dose range for this rare tumour and how this may vary with tumour size. This could be confirmed with further prospective evaluation accounting for the confounding variables identified, although the uncommon nature of this tumour suggests that a multi-institutional approach would be required.
In conclusion, this study demonstrates that there is a relationship between dose (EQD2) and outcome. With increasing dose (EQD2), the likelihood of regression was higher and these results were statistically significant. When adjusted for PTV, the response was stronger. Based on this study alone, the radiation dose for this type of tumour varied significantly with changes in the size of the PTV.
